Babylon Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Babylon in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Babylon stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BBLN, but not buy additional shares or sell existing shares.
View analyst ratings for Babylon or view top-rated stocks.

7 Wall Street analysts have issued 12 month price objectives for Babylon's shares. Their BBLN stock forecasts range from $1.50 to $10.00. On average, they predict Babylon's stock price to reach $6.00 in the next year. This suggests a possible upside of 455.6% from the stock's current price.
View analysts' price targets for Babylon or view top-rated stocks among Wall Street analysts.

Babylon's stock was trading at $5.83 at the beginning of 2022. Since then, BBLN stock has decreased by 81.5% and is now trading at $1.08.
View the best growth stocks for 2022 here.

Babylon saw a increase in short interest in May. As of May 31st, there was short interest totaling 1,140,000 shares, an increase of 119.9% from the May 15th total of 518,300 shares. Based on an average daily trading volume, of 961,500 shares, the days-to-cover ratio is presently 1.2 days. Currently, 1.2% of the company's stock are sold short.
View Babylon's Short Interest.

Babylon is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Babylon.

Babylon Holdings Limited (NYSE:BBLN) released its quarterly earnings data on Thursday, May, 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.01. The company had revenue of $266.45 million for the quarter, compared to analysts' expectations of $238.49 million.
View Babylon's earnings history.

Babylon issued an update on its FY 2022 earnings guidance on Thursday, June, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.00B-, compared to the consensus revenue estimate of $966.89 million.

Some companies that are related to Babylon include P3 Health Partners (PIII), UpHealth (UPH), Covalon Technologies (CVALF), Better Therapeutics (BTTX), Mitesco (MITI), Xcelerate (XCRT), Union Dental (UDHI), Accelera Innovations (ACNV), Advanzeon Solutions (CHCR) and DCC (DCCPF).
View all of BBLN's competitors.

Babylon trades on the New York Stock Exchange (NYSE) under the ticker symbol "BBLN."

Babylon's stock is owned by many different retail and institutional investors. Top institutional investors include Qube Research & Technologies Ltd (0.79%), Nicholas Investment Partners LP (0.23%), Goldman Sachs Group Inc. (0.11%) and Renaissance Technologies LLC (0.10%).

BBLN stock was acquired by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Qube Research & Technologies Ltd, Renaissance Technologies LLC, and Goldman Sachs Group Inc..

Shares of BBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BBLN stock can currently be purchased for approximately $1.08.

Babylon (NYSE:BBLN) has a market capitalization of $46.58 million and generates $322.92 million in revenue each year.

Babylon employs 2,573 workers across the globe.

The official website for Babylon is www.babylonhealth.com. The company can be reached via phone at 44 20 7100 0762 or via email at [email protected].